- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
Patent holdings for IPC class C07K 14/71
Total number of patents in this class: 2154
10-year publication summary
|
106
|
134
|
140
|
153
|
144
|
204
|
218
|
169
|
156
|
108
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Acceleron Pharma Inc. | 360 |
144 |
| Regeneron Pharmaceuticals, Inc. | 4288 |
133 |
| Amgen Inc. | 4076 |
36 |
| The Regents of the University of California | 19961 |
31 |
| Immatics Biotechnologies GmbH | 1156 |
31 |
| Keros Therapeutics, Inc. | 65 |
25 |
| Board of Regents, The University of Texas System | 5808 |
22 |
| The Board of Trustees of the Leland Stanford Junior University | 6428 |
21 |
| The Trustees of the University of Pennsylvania | 4323 |
21 |
| Genentech, Inc. | 3976 |
20 |
| City of Hope | 994 |
20 |
| Immunitybio, Inc. | 378 |
20 |
| Genzyme Corporation | 1262 |
18 |
| The Johns Hopkins University | 5675 |
16 |
| Biocon Limited | 219 |
16 |
| Precigen Inc | 100 |
16 |
| Novartis AG | 10744 |
15 |
| Merck Patent GmbH | 5815 |
15 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3361 |
15 |
| National Research Council of Canada | 1547 |
15 |
| Other owners | 1504 |